ORION Biotech Catalyst Calendar
Menu
Skip to company dates

Alumis (ALMS) pipeline and stated timing

Name in SEC filings: ALUMIS INC.

Pipeline at a glance

ProgramEventStageStated timingFiling
envudeucitinib/data readoutPhase 2 20268-K ·
envudeucitinib submission— 20268-K ·

Source: ORION, orionbiotechai.com/company/ALMS, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/ALMS

Nearest upcoming stated timing: envudeucitinib · Topline/data readout · 2H 2026

SEC sources last checked .

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .

Program / eventStated period and SEC wordingDisclosure in stated period
envudeucitinibSubmission4Q 2026
“Alumis remains on track to submit an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in 4Q 2026”

Filed · EX-99.1

Still within period

As of Oct 19, 2026

envudeucitinibClinical results2H 2026
“Envudeucitinib in Moderate-to-Severe Plaque Psoriasis o Long-term data: Phase 2, two-year safety data (2H 2026)”

Filed · EX-99.1

Still within period

As of Oct 19, 2026

envudeucitinibSubmissionfourth quarter of 2026
“we plan to submit an NDA for envu for PsO in the fourth quarter of 2026”

Filed · 10-Q

Not compared

ORION has no confirmed start and end dates for this wording, so it is not compared with filings.

envudeucitinibSubmissionsecond half of 2026
“we plan to submit an NDA for envu for PsO in the second half of 2026”

Filed · 10-Q

Not compared

ORION has no confirmed start and end dates for this wording, so it is not compared with filings.

envudeucitinibSubmissionsecond half of 2026
“we plan to submit an NDA for envu for PsO in the second half of 2026”

Filed · 10-K

Not compared

ORION has no confirmed start and end dates for this wording, so it is not compared with filings.

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Watch ALMS

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for ALMS. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window
The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date
The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q
First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original
The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status
One of seven labels set by founder review of the original filings. Definitions: Methodology.

See ALMS in the calendar · Review labels and methodology

Topline results are the main summary results of a clinical trial, released before the full data.1H means January–June and 2H means July–December of the stated year, unless the company uses a different fiscal year.A New Drug Application (NDA) or Biologics License Application (BLA) asks the FDA to approve a drug or biologic for sale.Q1–Q4 (also written 1Q–4Q) are quarters of the year: Q1 is January–March, Q2 April–June, Q3 July–September and Q4 October–December, unless the company uses a different fiscal year.